New Patent Wins Secure Anaphylm Exclusivity Into 2037
Aquestive Therapeutics is making a strategic leap forward after the U.S. Patent and Trademark Office issued two additional patents for Anaphylm, its under-development oral epinephrine sublingual film. These patents extend protection until at least May 4, 2037, cementing the company’s intellectual property advantage just as the FDA weighs Anaphylm’s market entry.
Patents Strengthen Market Position Ahead of Key FDA Milestone
The newly granted U.S. patent numbers 12,427,121 and 12,443,850 secure composition-of-matter claims for the drug’s epinephrine prodrug formulation and its unique oral mucosal delivery system. With a Prescription Drug User Fee Act (PDUFA) target date set for January 31, 2026, Anaphylm could become the first and only orally administered product for anaphylaxis, pending FDA approval. This comes at a crucial time for the company as it prepares to challenge conventional, injection-based rescue treatments—long a source of hesitation for needle-averse patients.
Anaphylm: A Patient-Friendly Alternative to Injections
Anaphylm’s film, similar in size to a postage stamp and weighing less than an ounce, is designed to dissolve rapidly under the tongue without water or swallowing. The product aims to eliminate common barriers associated with epinephrine autoinjectors—needle fear, bulkiness, and inconvenience—potentially broadening access for millions managing severe allergic reactions.
| Key Feature | Details |
|---|---|
| Product | Anaphylm (dibutepinephrine) Sublingual Film |
| Patent Expiration | May 4, 2037 |
| Delivery | Oral sublingual film, dissolves without water |
| PDUFA Date | January 31, 2026 |
| Stock Price (11:58 AM) | $6.59 |
Potential Industry Disruption: Needle-Free Rescue for Anaphylaxis?
The traditional approach to anaphylaxis relies on autoinjectors, but adoption rates are challenged by needle phobia and convenience issues. Aquestive’s patent wins solidify a runway to commercialize a more user-friendly option—assuming successful regulatory clearance and acceptance by healthcare professionals and patients. These factors could set the stage for a reshaping of the severe allergy emergency market over the coming decade.
Looking Forward: Market Impact and Remaining Uncertainties
While the new patents reinforce Aquestive’s intellectual property moat, investors should consider regulatory risks and potential market hurdles—including competition, FDA demands for more data, and the real-world uptake of a novel oral alternative. The next major milestone is the FDA’s PDUFA decision in early 2026, which will determine if Anaphylm can be the first-to-market, needle-free solution for a long-standing patient need.
With robust patent protection in place and a potential FDA decision less than two years away, the landscape for allergy emergency care could look very different by the end of this decade. Will patients embrace a film over a shot? That question may soon move from speculation to market reality.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI